Who is sponsoring NCT05307770?

NCT05307770 is sponsored by Mayo Clinic.

What drugs are being tested in NCT05307770?

Interventions in NCT05307770: Immediate Release Melatonin, Extended Release Melatonin.

What condition does NCT05307770 study?

NCT05307770 studies Rapid Eye Movement Sleep Behavior Disorder, Parkinson Disease.

Is NCT05307770 still recruiting?

NCT05307770 is currently terminated. Last updated 29 May 2024.

Last reviewed 2024-05-29 · How we verify

NCT05307770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

Terminated NA Last updated 29 May 2024

What this trial tests

NA trial testing Immediate Release Melatonin in Rapid Eye Movement Sleep Behavior Disorder in 25 participants. Terminated before completion.

Timeline

1 May 2022

Primary endpoint
1 February 2024

1 February 2024

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	supportive care
Enrollment	25
Start date	1 May 2022
Primary completion	1 February 2024
Estimated completion	1 February 2024
Sites	1 location across United States

Drugs / interventions tested

Immediate Release Melatonin
Extended Release Melatonin

Conditions studied

Rapid Eye Movement Sleep Behavior Disorder — all drugs for Rapid Eye Movement Sleep Behavior Disorder →
Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Rapid Eye Movement Sleep Behavior Disorder or Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with Parkinson disease and Rapid Eye Movement Sleep Behavior Disorder.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Melatonin: Facts, Extrapolations and Clinical Trials.
Boutin JA, Kennaway DJ, Jockers R. · · 2023 · cited 55× · PMID 37371523 · DOI 10.3390/biom13060943
Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.
Íñigo-Catalina L, Ortiz-Cabello M, Navarro E, Esteras N, et al · · 2025 · cited 2× · PMID 41154499 · DOI 10.3390/antiox14101190

Verify or expand the search:

Other recruiting trials for Rapid Eye Movement Sleep Behavior Disorder

Currently open trials in the same condition.

NCT06710574 — Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease · Phase 4 · recruiting
NCT04534023 — A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies · Phase 2 · active not recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05307770 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 29 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05307770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing